1. P971: ADJUSTED COMPARISON OF PATIENT REPORTED OUTCOMES FROM CARTITUDE-1 AND LOCOMMOTION COMPARING CILTACABTAGENE AUTOLEUCEL VERSUS REAL WORLD CLINICAL PRACTICE IN TRIPLE-CLASS EXPOSED MULTIPLE MYELOMA. (23rd June 2022) Authors: Weisel, K.; Mateos, M.-V.; Vincent, L.; Martin, T.; Berdeja, J. G.; Jakubowiak, A.; Jagannath, S.; Lin, Y.; Thilakarathne, P.; Ghilotti, F.; Diels, J.; Haefliger, B.; Hague, C.; Gonzalez, A.; Schecter, J. M.; Gries, K. S.; Strulev, V.; Nesheiwat, T.; Pacaud, L.; Einsele, H. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 861 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P960: HEALTH-RELATED QUALITY OF LIFE IN THE LOCOMMOTION STUDY OF REAL-LIFE CURRENT STANDARD OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA. (23rd June 2022) Authors: Delforge, M.; Moreau, P.; Einsele, H.; De Stefano, V.; Lindsey-Hill, J.; Vincent, L.; Mangiacavalli, S.; Perrot, A.; Ocio, E.; ten Seldam, S.; '. Groen-Damen, E. I.; Semerjian, M.; Strulev, V.; Schecter, J. M.; Roccia, T.; Gries, K. S.; Nesheiwat, T.; Wapenaar, R.; Mateos, M.-V.; Weisel, K. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 850 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P958: REAL-LIFE CURRENT STANDARD OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSES FROM THE LOCOMMOTION STUDY. (23rd June 2022) Authors: Einsele, H.; Moreau, P.; De Stefano, V.; Dytfeld, D.; Angelucci, E.; Benjamin, R.; Goldschmidt, H.; van de Donk, N. W.; Besemer, B.; Scheid, C.; Vij, R.; '. Groen-Damen, E. I.; Semerjian, M.; Strulev, V.; Schecter, J. M.; Roccia, T.; Nesheiwat, T.; Wapenaar, R.; Weisel, K.; Mateos, M.-V. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 848 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P935: REAL WORLD COMPARATIVE ANALYSIS OF THE EFFICACY OF TECLISTAMAB VERSUS CURRENT TREATMENTS IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE LOCOMOTION STUDY. (23rd June 2022) Authors: Einsele, H.; Moreau, P.; Delforge, M.; van de Donk, N. W.; Ghilotti, F.; Diels, J.; Elsada, A.; Strulev, V.; Pei, L.; Kobos, R.; Smit, J.; Slavcev, M.; Weisel, K.; Mateos, M.-V. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 825 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗